Talazoparib (Talzenna) for Prostate Cancer

Found an issue? Give us feedback

The Medical Letter o...arrow_drop_down

The Medical Letter on Drugs and Therapeutics

Article . 2023 . Peer-reviewed

Data sources: Crossref

The Medical Letter on Drugs and Therapeutics

Article . 2023

Data sources: Europe PubMed Central

Talazoparib (Talzenna) for Prostate Cancer

descriptionPublicationkeyboard_double_arrow_right Article 07 Aug 2023Publisher:The Medical Letter, Inc.Journal:The Medical Letter on Drugs and Therapeutics, volume 65, pages e134-e135 (eissn: 1523-2859,

Copyright policy )

doi: 10.58347/tml.2023.1682e

pmid: 37541769

Talazoparib (Talzenna) for Prostate Cancer

- Summary
- Subjects
- Metrics

Abstract

The oral poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib (Talzenna – Pfizer) has been approved by the FDA for use in combination with the androgen receptor blocker enzalutamide (Xtandi) for treatment of adults with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).

Keywords

Male, Nitriles, Humans, Prostatic Neoplasms, Phthalazines

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average